ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Dopamine: Pediatric drug information

Dopamine: Pediatric drug information
(For additional information see "Dopamine: Drug information" and see "Dopamine: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Therapeutic Category
  • Adrenergic Agonist Agent;
  • Sympathomimetic
Dosing: Neonatal
Hemodynamic support

Hemodynamic support: Neonates: Continuous IV or intraosseous infusion: 2 to 20 mcg/kg/minute; titrate gradually by 5 to 10 mcg/kg/minute increments until optimal response is obtained (Ref). Note: Dopamine has a dose-dependent effect; low doses (<5 mcg/kg/minute) augment renal blood flow and urine output; intermediate doses (5 to 15 mcg/kg/minute) increase renal blood flow, heart rate, cardiac contractility, cardiac output, and blood pressure; high doses (>15 mcg/kg/minute) result in vasoconstriction and increased blood pressure (Ref).

Dosing: Pediatric
Hemodynamic support

Hemodynamic support: Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: 2 to 20 mcg/kg/minute; titrate gradually by 5 to 10 mcg/kg/minute increments until optimal response is obtained (Ref). Note: Dopamine has a dose-dependent effect; doses at lower end of this range are preferred, as inotropic actions predominate at lower doses and vasoconstrictive actions predominate at higher doses (Ref).

Dosing: Adult

(For additional information see "Dopamine: Drug information")

Note: Hemodynamic effects of dopamine are dose dependent (however, this is relative and there is overlap of clinical effects between dosing ranges) (Ref).

Low dose: Augments renal dopamine receptors, which may increase renal blood flow and urine output. The use of low-dose dopamine to prevent or treat acute kidney injury is not recommended.

Intermediate dose: Dopamine and beta-adrenergic effects predominate, resulting in increased renal blood flow, heart rate, cardiac contractility, and cardiac output.

High dose: Alpha-adrenergic effects begin to predominate, resulting in vasoconstriction and increased blood pressure, in addition to increased heart rate, cardiac contractility, and cardiac output due to beta-adrenergic effects.

Bradycardia or atrioventricular block, symptomatic

Bradycardia or atrioventricular block, symptomatic (unresponsive to atropine) (off-label use):

Continuous infusion: IV: Initial: 5 mcg/kg/minute; increase by 5 mcg/kg/minute every 2 minutes until desired effect; maximum dose: 20 mcg/kg/minute (Ref).

Hypotension or shock

Hypotension or shock:

Cardiogenic shock (alternative agent):

Note: Typically, not the preferred initial agent in cardiogenic shock; consider other inotropic and/or vasopressor options; caution with the use of dopamine due to increased arrhythmias and possibly mortality in this population (Ref). Optimal goal of therapy not well established, but typically titrate to maintain end-organ perfusion (Ref).

Continuous infusion: IV: Usual dosage range: 0.5 to 20 mcg/kg/minute; titrate based on clinical end point (eg, end-organ perfusion) (Ref).

Septic shock and other vasodilatory shock states (alternative agent):

Note: Not recommended for septic shock except as an alternative to norepinephrine in patients with bradycardia who have a low risk of tachyarrhythmias (Ref). Compared to norepinephrine, dopamine is associated with an increased risk of tachyarrhythmias and potentially worse outcomes (eg, increased mortality, kidney failure) (Ref). In general, maintain goal mean arterial pressure (MAP) (eg, ~65 mm Hg); consider use if patient is in shock or has hypoperfusion during or after fluid resuscitation (Ref).

Continuous infusion: IV: Initial: 2 to 5 mcg/kg/minute; titrate to goal MAP up to a dose of 20 mcg/kg/minute (Ref).

Post–cardiac arrest shock (alternative agent):

Note: Typically, not the preferred initial agent in post–cardiac arrest shock due to risk of tachyarrhythmias; consider other inotropic and/or vasopressor options (Ref). Optimal goal of therapy is not well established, but typically titrate to MAP >65 mm Hg and preferably >80 mm Hg to optimize cerebral and end-organ perfusion (Ref).

Continuous infusion: IV: Usual dosage range: 5 to 20 mcg/kg/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion) (Ref).

Inotropic support

Inotropic support:

Note: May consider in patients with severe systolic dysfunction with decreased end-organ perfusion (Ref).

Continuous infusion: IV: 5 to 15 mcg/kg/minute; doses at lower end of this range are preferred as inotropic actions predominate at lower doses and vasoconstrictive actions predominate at higher doses (Ref).

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Postmarketing:

Cardiovascular: Angina pectoris, atrial fibrillation, bradycardia, cardiac conduction disorder, ectopic beats, hypertension, hypotension, palpitations, tachycardia, vasoconstriction, ventricular arrhythmia, widened QRS complex on ECG

Dermatologic: Peripheral gangrene (with prolonged or high dose, can occur with low doses with concomitant occlusive vascular disease), piloerection

Gastrointestinal: Nausea, vomiting

Genitourinary: Azotemia

Nervous system: Anxiety, headache

Respiratory: Dyspnea

Contraindications

Pheochromocytoma.

Warnings/Precautions

Concerns related to adverse effects:

• Arrhythmias: May cause increases in heart rate, increasing the risk of tachycardia and other tachyarrhythmias including ventricular arrhythmias (Tisdale 1995). In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Young 2000).

• Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; infuse into a large vein if possible. Avoid infusion into leg veins. Watch IV site closely. If extravasation occurs, infiltrate the area with diluted phentolamine (5 to 10 mg in 10 mL of saline) with a fine hypodermic needle. Phentolamine should be administered as soon as possible after extravasation is noted to prevent sloughing/necrosis (Stefanos 2023).

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with cardiovascular disease, cardiac arrhythmias and/or occlusive vascular disease.

• Active myocardial ischemia/post-myocardial infarction: Use with caution in patients with active myocardial ischemia or recent myocardial infarction; may increase myocardial oxygen consumption.

• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias (ACC/AHA/ESC [Zipes 2006]; Tisdale 1995).

• Shock: The use of dopamine in adult patients with shock (majority of patients had septic shock) demonstrated a higher incidence of adverse events (eg, tachyarrhythmias) (De Backer 2010). Higher 28-day mortality was also seen in patients with septic shock with the use of dopamine as compared to norepinephrine (De Backer 2012; Vasu 2012).

Dosage form specific issues:

• Sodium metabisulfite: Product may contain sodium metabisulfite.

Other warnings/precautions:

• Appropriate use: Assure adequate circulatory volume to minimize need for vasoconstrictors when used in hemodynamic support. Avoid hypertension; monitor blood pressure closely and adjust infusion rate.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous, as hydrochloride:

Generic: 0.8 mg/mL (250 mL, 500 mL); 1.6 mg/mL (250 mL, 500 mL); 3.2 mg/mL (250 mL); 40 mg/mL (5 mL, 10 mL)

Solution, Intravenous, as hydrochloride [preservative free]:

Generic: 40 mg/mL (5 mL, 10 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (DOPamine HCl Intravenous)

40 mg/mL (per mL): $0.70 - $0.86

Solution (DOPamine in D5W Intravenous)

0.8 mg/mL 5% (per mL): $0.06

1.6 mg/mL 5% (per mL): $0.07

3.2 mg/mL 5% (per mL): $0.09 - $0.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 0.8-5 MG/ML-% (250 mL); 1.6-5 MG/ML-% (250 mL, 500 mL); 3.2-5 MG/ML-% (250 mL, 500 mL)

Administration: Pediatric

Parenteral: Continuous IV infusion: Vials (concentrated solution) must be diluted prior to administration; premixed IV solutions (800 mcg/mL, 1,600 mcg/mL, 3,200 mcg/mL) are available. Administer as a continuous IV infusion with the use of an infusion pump or an intraosseous infusion until IV access can be obtained in pediatric patients (Ref). Administer into large vein to minimize the possibility of extravasation (central line administration); administration into an umbilical arterial catheter is not recommended (Ref). If central line is not available, may administer for a short duration through a peripheral IV catheter placed in a large vein or via intraosseous access using a more dilute solution or with a second carrier fluid; once central access is available, begin central line infusion and wait for pharmacologic effect prior to stopping peripheral administration (Ref). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (Ref). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Do not administer sodium bicarbonate (or any alkaline solution) through an IV line containing dopamine; inactivation of dopamine may occur (Ref). Avoid abrupt discontinuation; reduce infusion flow rate slowly.

Rate of infusion (mL/hour) = [dose (mcg/kg/minute) × weight (kg) × 60 minutes/hour] divided by concentration (mcg/mL)

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative) antidote (see Management of Drug Extravasations for more details). Apply dry warm compresses (Ref).

Administration: Adult

IV: Administer as a continuous infusion via an infusion pump. Central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may administer for a short duration (<72 hours) through a peripheral IV catheter placed in a large vein at a proximal site (eg, in or proximal to antecubital fossa). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (Ref). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution.

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do NOT flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry, warm compresses; initiate phentolamine (or alternative) antidote (Ref).

Phentolamine: SUBQ: Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose intravenously through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (Ref).

Alternatives to phentolamine:

Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected areas; may repeat every 8 hours as necessary (Ref).

Terbutaline:

Large extravasations: SUBQ: Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS; may repeat dose after 15 minutes (Ref).

Small extravasations: SUBQ: Infiltrate affected extravasation area with 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (Ref).

Usual Infusion Concentrations: Neonatal

Note: Premixed solutions available.

IV infusion: 1,600 mcg/mL or 3,200 mcg/mL.

Usual Infusion Concentrations: Pediatric

Note: Premixed solutions available.

IV infusion: 800 mcg/mL, 1,600 mcg/mL, or 3,200 mcg/mL.

Storage/Stability

Store vials and premixed single-use containers at 20°C to 25°C (68°F to 77°F). Avoid excessive heat; brief exposure of premixed single-use containers of up to 40°C (104°F) does not adversely affect the product. Protect from freezing. Dopamine has been found to be stable for a minimum of 24 hours after dilution in a compatible solution. Avoid contact or simultaneous administration with alkalies (including sodium bicarbonate), oxidizing agents, or iron salts.

Use

Treatment of hypotension or shock (eg, septic shock and other vasodilatory shock states, cardiogenic shock, decompensated heart failure, post cardiac arrest) that persists after adequate fluid volume replacement (FDA approved in all ages).

Medication Safety Issues
Sound-alike/look-alike issues:

DOPamine may be confused with DOBUTamine, Dopram

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Metabolism/Transport Effects

Substrate of COMT, OCT1, OCT2

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. Risk C: Monitor therapy

Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Risk D: Consider therapy modification

Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting). Risk C: Monitor therapy

Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days. Risk D: Consider therapy modification

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider therapy modification

COMT Inhibitors: May increase the serum concentration of COMT Substrates. Risk C: Monitor therapy

Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Risk C: Monitor therapy

Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Risk X: Avoid combination

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy

Hyaluronidase: May enhance the adverse/toxic effect of DOPamine. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine. Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated. Risk D: Consider therapy modification

Inhalational Anesthetics: May enhance the arrhythmogenic effect of DOPamine. Risk C: Monitor therapy

Kratom: May enhance the adverse/toxic effect of Sympathomimetics. Risk X: Avoid combination

Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine. Risk C: Monitor therapy

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Risk D: Consider therapy modification

Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Risk X: Avoid combination

Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of DOPamine. Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine. Risk D: Consider therapy modification

Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy

Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache). Risk D: Consider therapy modification

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Risk C: Monitor therapy

Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist. Risk D: Consider therapy modification

Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. Risk C: Monitor therapy

Pregnancy Considerations

Medications required for the treatment of critically ill pregnant patients should not be withheld due to concerns of fetal teratogenicity (ACOG 2019; AHA [Jeejeebhoy 2015]). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant patients. Dopamine use during the postresuscitation phase may be considered; however, the effects of vasoactive medications on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines (AHA [Jeejeebhoy 2015]).

Monitoring Parameters

Blood pressure, ECG, heart rate, central venous pressure, mean arterial pressure, urine output; if pulmonary artery catheter is in place, monitor cardiac index, pulmonary capillary wedge pressure, systemic vascular resistance, right atrial pressure, and pulmonary vascular resistance; monitor for skin color and temperature changes.

Mechanism of Action

Stimulates both adrenergic and dopaminergic receptors, lower doses are mainly dopaminergic stimulating and produce renal and mesenteric vasodilation, higher doses also are both dopaminergic and beta1-adrenergic stimulating and produce cardiac stimulation and renal vasodilation; large doses stimulate alpha-adrenergic receptors

Pharmacokinetics (Adult Data Unless Noted)

Note: Children: Dopamine has exhibited nonlinear kinetics in children; with dose changes, may not achieve steady-state for ~1 hour rather than 20 minutes.

Onset of action: Adults: Within 5 minutes.

Duration: Adults: <10 minutes.

Metabolism: Renal, hepatic, plasma; 75% to inactive metabolites by monoamine oxidase and 25% to norepinephrine (active).

Half-life elimination: ~2 minutes.

Excretion: Urine (as metabolites).

Clearance: Neonates: Varies and appears to be age related; clearance is more prolonged with combined hepatic and kidney dysfunction.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Dopamin | Dopamine | Dopmin;
  • (AR) Argentina: Dopamina duncan | Dopamina northia | Dopamina surar pharma | Dopatropin | Hettytropin | Inotropin | Megadose;
  • (AT) Austria: Dopamin | Dopamin ebewe | Dopamin Solvay;
  • (AU) Australia: Dopamine | Dopamine juno;
  • (BD) Bangladesh: Cardopa | Dopamin | Myomine;
  • (BE) Belgium: Dynatra;
  • (BG) Bulgaria: Dopamin | Dopamin Admeda | Dopmin;
  • (BR) Brazil: Cloridrato de dopamina | Constriction | Dopabane | Dopacris | Dopamin | Dopamina | Dopamol | Inotropisa | Revimine | Revivan;
  • (CH) Switzerland: Dopamin braun | Dopamin fresenius | Dopamin Giulini | Dopamin Sintetica;
  • (CN) China: Dopamine;
  • (CO) Colombia: Cardiopal | Dopamina | Inotropisa | Myofast;
  • (CZ) Czech Republic: Dopamin | Dopamin Admeda;
  • (DE) Germany: Dopamin | Dopamin natter | Dopamin Solvay;
  • (DO) Dominican Republic: Dopamina;
  • (EC) Ecuador: Dopamina;
  • (EE) Estonia: Dopamin | Dopamina grifols | Dopamine | Dopamine wzf polfa | Dopmin;
  • (EG) Egypt: Dopamine | Dopasunny;
  • (ES) Spain: Aprical dopamida | Dopamina fides | Dopamina grifols;
  • (ET) Ethiopia: Dopadren | Dopamine;
  • (FI) Finland: Abbodop | Dopmin;
  • (FR) France: Dopamine aguettant | Dopamine lucien | Dopamine merck | Dopamine nativelle | Dopamine PCH | Dopamine pierre fabre | Dopamine Renaudin;
  • (GB) United Kingdom: Dopamine | Dopamine premix | Ims dopamine | Intropin | Intropin ahs;
  • (GR) Greece: Dopamine hycrochloride | Giludop;
  • (HU) Hungary: Dopamin Giulini | Dopamin Solvay;
  • (ID) Indonesia: Cetadop | Dopac | Dopamin | Dopamin Giulini | Dopamine hcl abbott | Doperba | Indop | Oridop | Proinfark | Udopa;
  • (IE) Ireland: Dopamine;
  • (IN) India: Domin | Dopacef | Dopacin | Dopamine | Dopamine-p | Dopan | Dopinga | Dopress;
  • (IT) Italy: Dopamina abbott | Dopamina cloridrato | Dopamina pht | Dopamina salf | Revivan;
  • (JO) Jordan: Domine | Dopamine | Dopamine fresenius;
  • (JP) Japan: Actopamin | Catabon | Catherine | Catherine amel | Corskool | Critpan | Dasomin | Dolpamil | Dominin | Donapan | Doncal | Dopa kit | Dopamine | Dopamine hydrochloride kobayashi | Dopamine Hydrochloride Mochida | Dopamine Hydrochloride Shionogi | Dopamine towa | Dopaminex | Doparalmin | Elebumin | Evetant hexal | Evetant towa | Gabans | Inovan | Kakodin | Martburn | Mitasmin | Predopa | Predopa Kyowa | Predopa merck hoei | Seminiet | Taiadopa | Tronjin | Tsurudopami | Yaelista | Yaelista mita;
  • (KR) Korea, Republic of: Domine | Domins | Dopamine | Dopamine injection huons | Dopaminex | Dopan | Dopasin | Dopramin | Inophan | Tropin | Udopa;
  • (KW) Kuwait: Dopamine | Intropin;
  • (LB) Lebanon: Dopamine | Dopamine Renaudin;
  • (LT) Lithuania: Dopamin | Dopamin Giulini | Dopmin;
  • (LU) Luxembourg: Dopamin | Dynatra;
  • (LV) Latvia: Dopamin | Dopmin;
  • (MX) Mexico: Dopamina | Dopamina 3m | Dopamina exakta | Dopamina gi zafiro | Dopamina kendrick | Flemina | Inotropin | Inotropisa | Zetarina;
  • (MY) Malaysia: Dopaine | Dopamine | Dopmin;
  • (NL) Netherlands: Dopamine | Dopaminehydrochloride Eureco Pharma | Dynatra;
  • (NO) Norway: Abbodop | Dopamin;
  • (NZ) New Zealand: Dopamine | Sterile dopamine concentrate;
  • (PE) Peru: Dopamina | Dopamina clorhidrato | Intropin;
  • (PH) Philippines: Abbott dopamine hcl | Dopabas | Dopamax | Dopaqard | Dopnax | Doprina | Myocard | Myotil;
  • (PK) Pakistan: Dopamine | Dopasid | Dopna | Tropin;
  • (PL) Poland: Dopamin Giulini | Dopaminum hydrochloricum;
  • (PR) Puerto Rico: Dopamine HCL;
  • (PT) Portugal: Cordodopa | Cordodopa Forte | Dopamina | Dopamina basi | Medopa;
  • (PY) Paraguay: Dopamina duncan | Dopamina northia;
  • (RO) Romania: Clorhidrat de dopamina;
  • (RU) Russian Federation: Dofamin | Dofamine | Dofamine Ferein | Dofamine n.s. | Dopamin | Dopamin Admeda | Dopamin Solvay | Dopamine | Dopmin;
  • (SA) Saudi Arabia: Domine | Dopamine | Dopamine HCL | Intropin;
  • (SE) Sweden: Giludop;
  • (SG) Singapore: Dopamine;
  • (SI) Slovenia: Dopamin;
  • (SK) Slovakia: Dopamine;
  • (TH) Thailand: Domin | Dopamex | Dopamin hausmann | Dopamine | Dopamine abbott | Dopamine HCL | Dopamine hydrochloride dbl | Dopaminex | Dopin | Dopmin | Inopin | Upamine;
  • (TN) Tunisia: Dopamine | Dopamine mylan;
  • (TR) Turkey: Dopadren | Dopamine | Dopamine fresenius | Dopasel | Dopmin | Giludop;
  • (TW) Taiwan: Dopamin | Dopamin Giulini | Dopamine | Dopamine HCL | Dopavate | Dopmin | Easydopa | Gipamine | Intropin | Revivan | Uramin | Vidopa;
  • (UA) Ukraine: Dofamin darnitsa | Dopamin | Dopamin Admeda | Dopmin;
  • (UG) Uganda: Dopamine hcl-fresenius;
  • (UY) Uruguay: Bagotropin | Dopamin | Dopamina | Dopamina fu | Megadose;
  • (VE) Venezuela, Bolivarian Republic of: Dopamina | Dopina | Myotil;
  • (ZA) South Africa: Dopamine | Dopamine hcl-fresenius | Micro Dopamine;
  • (ZM) Zambia: Pharma q dopamine
  1. Adams C, Tucker C, Allen B, et al. Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. J Crit Care. 2017;37:219-223. doi:10.1016/j.jcrc.2016.10.004 [PubMed 27969574]
  2. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 211: Critical care in pregnancy. Obstet Gynecol. 2019;133(5):e303-e319. doi:10.1097/AOG.0000000000003241 [PubMed 31022122]
  3. American Heart Association (AHA). CPR & First Aid: Emergency Cardiovascular Care. Adult Bradycardia Algorithm. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/algorithms. Published 2020. Accessed January 29, 2021.
  4. American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed April 4, 2022.
  5. Arabi YM, Dara SI, Tamim HM, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study. Crit Care. 2013;17(2):R72. doi:10.1186/cc12680 [PubMed 23594407]
  6. Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med. 2005;33(6):1327-1332. [PubMed 15942351]
  7. Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015;10(8):e0129305. doi:10.1371/journal.pone.0129305 [PubMed 26237037]
  8. Bellomo R, Chapman M, Finfer S, et al. Low-dose Dopamine in Patients With Early Renal Dysfunction: A Placebo-Controlled Randomised Trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000;356(9248):2139-2143. [PubMed 11191541]
  9. Callaway CW, Donnino MW, Fink EL, et al. Part 8: Post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care [published correction appears in Circulation. 2017 Sep 5;136(10 ):e197]. Circulation. 2015;132(18 suppl 2):S465-S482. doi:10.1161/CIR.0000000000000262 [PubMed 26472996]
  10. Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 2015;10(9):581-5. doi:10.1002/jhm.2394 [PubMed 26014852]
  11. Chan TY. Low-Dose Dopamine in Severe Right Heart Failure and Chronic Obstructive Pulmonary Disease. Ann Pharmacother. 1995;29(5):493-496. [PubMed 7655133]
  12. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310(23):2533-2543. [PubMed 24247300]
  13. Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine (ACCM) clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med. 2017;45(6):1061-1093. doi:10.1097/CCM.0000000000002425 [PubMed 28509730]
  14. De Backer D, Aldecoa C, Njimi H, et al. Dopamine versus Norepinephrine in the Treatment of Septic Shock: A Meta-Analysis. Crit Care Med. 2012;40(3):725-730. [PubMed 22036860]
  15. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789. [PubMed 20200382]
  16. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637. doi:10.1097/CCM.0b013e31827e83af [PubMed 23353941]
  17. Dempsey E, Rabe H. The use of cardiotonic drugs in neonates. Clin Perinatol. 2019;46(2):273-290. doi:10.1016/j.clp.2019.02.010 [PubMed 31010560]
  18. Denkler KA, Cohen BE. Reversal of dopamine extravasation injury with topical nitroglycerin ointment. Plast Reconstr Surg. 1989;84(5):811-813. [PubMed 2510208]
  19. Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Lippincott Williams & Wilkins; 2017.
  20. Dopamine HCL injection solution [prescribing information]. Shirley, NY: American Regent Inc; March 2014.
  21. Dopamine Hydrochloride Injection (Fliptop, Pintop, LifeShield Fliptop Vials) [prescribing information]. Lake Forest, IL: Hospira; September 2023.
  22. Dopamine Hydrochloride in 5% Dextrose Injection [prescribing information]. Lake Forest, IL: Hospira; April 2021.
  23. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. Circulation. 2008;117(2):200-205. J Card Fail. 2010;16(12):922-930. [PubMed 18172028]
  24. Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. Crit Care. 2021;25(1):77. doi:10.1186/s13054-021-03495-8 [PubMed 33622380]
  25. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337 [PubMed 34605781]
  26. Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.
  27. Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):640-656. [PubMed 20956217]
  28. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142(7):510-524. [PubMed 15809463]
  29. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
  30. Hollenberg SM, Ahrens TS, Annane D, et al. Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update. Crit Care Med. 2004;32(9):1928-1948. [PubMed 15343024]
  31. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011;183(7):847-855. doi:10.1164/rccm.201006-0972CI [PubMed 21097695]
  32. Hurst S, McMillan M. Innovative Solutions in Critical Care Units: Extravasation Guidelines. Dimens Crit Care Nurs. 2004;23(3):125-128. [PubMed 15192356]
  33. Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network. Standard Concentrations of Neonatal Drug Infusions. 2011. https://www.ismp.org/Tools/PediatricConcentrations.pdf
  34. Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, Council on Clinical Cardiology. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. Circulation. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300 [PubMed 26443610]
  35. Johnson RL Jr. Low-Dose Dopamine and Oxygen Transport by the Lung. Circulation. 1998;98(2):97-99. [PubMed 9679713]
  36. Kellum JA, Decker J. Use of Dopamine in Acute Renal Failure: A Meta-Analysis. Crit Care Med. 2001;29(8):1526-1531. [PubMed 11505120]
  37. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012;2(suppl 1):1-138. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf.
  38. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):S876-S908. [PubMed 20956230]
  39. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):e51-e156. doi:10.1016/j.jacc.2018.10.044 [PubMed 30412709]
  40. Lamontagne F, Richards-Belle A, Thomas K, et al; 65 trial investigators. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. JAMA. 2020;323(10):938–49. doi:10.1001/jama.2020.0930 [PubMed 32049269]
  41. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 Update. Crit Care Med. 2018;46(6):997-1000. doi: 10.1097/CCM.0000000000003119 [PubMed 29767636]
  42. Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the peripheral administration of vasopressor agents. J Intensive Care Med. 2019;34(1):26-33. doi:10.1177/0885066616686035 [PubMed 28073314]
  43. Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 22, 2021.
  44. Martin C, Papazian L, Perrin G, et al. Norepinephrine or Dopamine for the Treatment of Hyperdynamic Septic Shock? Chest. 1993;103(6):1826-1831. [PubMed 8404107]
  45. Medlej K, Kazzi AA, El Hajj Chehade A, et al. Complications from administration of vasopressors through peripheral venous catheters: an observational study. J Emerg Med. 2018;54(1):47-53. doi:10.1016/j.jemermed.2017.09.007 [PubMed 29110979]
  46. Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71(17):1500-1508. [PubMed 25147175]
  47. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):S729-S767. [PubMed 20956224]
  48. Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916 [PubMed 33081529]
  49. Patel GP, Grahe JS, Sperry M, et al. Efficacy and Safety of Dopamine versus Norepinephrine in the Management of Septic Shock. Shock. 2010;33(4):375-380. [PubMed 19851126]
  50. Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):768-786. [PubMed 20956225]
  51. Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. Am J Health Syst Pharm. 2011;68(22):2176-2182. [PubMed 22058104]
  52. Prasanna N, Yamane D, Haridasa N, Davison D, Sparks A, Hawkins K. Safety and efficacy of vasopressor administration through midline catheters. J Crit Care. 2021;61:1-4. doi:10.1016/j.jcrc.2020.09.024 [PubMed 33049486]
  53. Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine dosing in obese and nonobese patients with septic shock. Am J Crit Care. 2016;25(1):27-32. doi:10.4037/ajcc2016667 [PubMed 26724290]
  54. Refer to manufacturer's labeling.
  55. Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617-632. [PubMed 24420913]
  56. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6 [PubMed 28101605]
  57. Russell JA, Gordon AC, Williams MD, Boyd JH, Walley KR, Kissoon N. Vasopressor therapy in the intensive care unit. Semin Respir Crit Care Med. 2021;42(1):59-77. doi:10.1055/s-0040-1710320 [PubMed 32820475]
  58. Sakr Y, Reinhart K, Vincent JL, et al. Does Dopamine Administration in Shock Influence Outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med. 2006;34(3):589-597. [PubMed 16505643]
  59. Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. Pediatrics. 2020;145(1):e20193450. [PubMed 31871244]
  60. Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. Pharmacotherapy. 2023;43(4):321-337. doi:10.1002/phar.2794 [PubMed 36938775]
  61. Stier PA, Bogner MP, Webster K, et al. Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia. Am J Emerg Med. 1999;17(1):91-94. [PubMed 9928712]
  62. Tian DH, Smyth C, Keijzers G, et al. Safety of peripheral administration of vasopressor medications: a systematic review. Emerg Med Australas. 2020;32(2):220-227. doi:10.1111/1742-6723.13406 [PubMed 31698544]
  63. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995;38(2):167-180. [PubMed 7568905]
  64. Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol. 2014;172(1):115-121. [PubMed 24485633]
  65. Vadiei N, Daley MJ, Murthy MS, Shuman CS. Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. Ann Pharmacother. 2017;51(3):194-202. doi:10.1177/1060028016682030 [PubMed 27886982]
  66. van de Borne P, Oren R, Somers VK. Dopamine Depresses Minute Ventilation in Patients With Heart Failure. Circulation. 1998;98(2):126-131. [PubMed 9679718]
  67. van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525 [PubMed 28923988]
  68. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):S836. [PubMed 20956228]
  69. Vasu TS, Cavallazzi R, Hirani A, et al. Norepinephrine or Dopamine for Septic Shock: Systematic Review of Randomized Clinical Trials. J Intensive Care Med. 2012;27(3):172-178. [PubMed 21436167]
  70. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med. 2020;21(2):e52-e106. doi:10.1097/PCC.0000000000002198 [PubMed 32032273]
  71. Wong AF, McCulloch LM, Sola A. Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates. J Pediatr. 1992;121(6):980-983. [PubMed 1447671]
  72. Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant. 2000;19(8)(suppl):s49-s57. [PubMed 11016488]
  73. Zipes DP, Camm AJ, Borggrefe M, et al; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-e484. [PubMed 16935995]
Topic 13248 Version 240.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟